DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
The insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020
The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period. The report also includes a discussion of the key vendors operating in this market.
A trend to note is the rising prices of insulin drugs. Apart from safety and efficacy, the cost of therapy plays a major role in deciding the number of consumers. The cost-effectiveness of a treatment needs to be analyzed while prescribing a therapy. However, due to the lack of alternative therapies, drugs like insulin are the standard treatment options despite their high cost. The insulin market in the US and Europe is expected to grow based on the rising prices of insulin analogs.
According to the report, a key growth driver is the advances in insulin delivery technology. The development of innovative insulin products and advances in insulin delivery technology have increased the life expectancy of individuals with diabetes. Automated injection devices such as insulin pumps and pens offers a safe and easy drug delivery option, increasing their demand in the market. For instance, NovoPen and FlexTouch by Novo Nordisk are the latest developments in durable insulin delivery devices.
Further, the report states that one challenge that could have an adverse impact on market growth is the complexity of the insulin production process.
Key vendors
- Sanofi
- Novo Nordisk
- Eli Lilly
Other prominent vendors
- Adocia
- Biocon
- Biodel
- Biogenomics
- Boehringer Ingelheim
- Dance Biopharm
- Diasome Pharmaceuticals
- Exsulin
- Generex
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- MannKind
- Macrogenics
- Merck
- Melior Pharmaceuticals
- Metabolic Solutions Development Company
- NGM Biopharmaceuticals
- NuSirt Biopharma
- Oramed Pharmceuticals
- PhaseBio Pharmaceuticals
- Pfizer
- Thermalin Diabetes
- Tolerion
- VeroScience
- vTv Therapeutics
- Wockhardt
- XOMA
Key Topics Covered:
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Assumptions
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Key buying criteria
PART 05: Major branded drug profiles
- Actrapid
- Apidra
- Humalog
- Insuman
- Lantus
- Levemir
- NovoMix
- NovoRapid
- Toujeo
- Tresiba
PART 06: Insulin: An overview
- History of insulin
- Epidemiology
- Reimbursement scenario
- Patent scenario for approved products
PART 07: Pipeline portfolio
- Xultophy (NN9068)
- Faster-acting insulin as
PART (NN1218)
- SAR342434
- LY2605541
- MK-1293
- Oral-Lyn
PART 08: Oral insulin therapies
- Upcoming vendors for oral insulin therapies
- Oramed Pharmaceuticals
- Generex Biotechnology
PART 09: Market landscape
- Global insulin market
- Insulin market in US and Europe
- Market size and forecast
- Five forces analysis
PART 10: Market segmentation by drug class
- Fast-acting insulin
- Intermediate-acting insulin
- Long-acting insulin
PART 11: Market segmentation by application
- Type 1 diabetes
- Type 2 diabetes
PART 12: Market segmentation by insulin delivery technologies
- Injectable insulin
- Oral insulin
- Inhaled insulin
- Other emerging insulin delivery technologies
- Insulin pumps
PART 13: Geographical segmentation
- Insulin market in US
- Insulin market in Europe
PART 14: Market drivers
- Advances in insulin delivery technology
- Unmet medical needs
- Increase in prevalence of diabetes and obesity
- Increase in awareness of diabetes
PART 15: Impact of drivers
PART 16: Market challenges
- Complexity of insulin production
- Poor storage condition and distribution policies
- Stringent regulatory environment
- Inconvenient ROA
PART 17: Impact of drivers and challenges
PART 18: Market trends
- Increase in R&D for novel mechanisms
- Increase in academia-industry collaborations for drug development
- Increasing price of insulin drugs
- Intense competition among present and upcoming vendors
PART 19: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/qnmtsw/insulin_market_in
